Furthermore, we examined the therapeutic effect of eIF4A3-IN-2 on BC-BM, which eIF4A3-IN-2 treatment was started when bioluminescence signal of bone-metastatic tumors reached 2 × 105 p/sec/cm2/sr (Fig. 7e). This evidence concerns the gene CD44 and metastatic neoplasm.